Stentys receives CE Marking for drug-eluting stent

Stentys announced today that it has received CE Marking for its drug-eluting stent.

“The clinical results of the Stentys DES in complex lesions have been spectacular, and we are thrilled that patients throughout Europe will have access to the benefits of our self-expanding stent in due course”

The unique self-expanding Stentys stent is designed to ensure optimal apposition of a stent in the critical initial hours and days after an AMI (acute myocardial infarction) procedure, by being continuously applied to the vessel's internal wall even during thrombus resolution and vessel spasm relief—thereby avoiding malapposition, a major predictor of stent thrombosis.

"The clinical results of the Stentys DES in complex lesions have been spectacular, and we are thrilled that patients throughout Europe will have access to the benefits of our self-expanding stent in due course," said Gonzague Issenmann, CEO and co-founder of Stentys.

Stentys will host a symposium on the treatment of acute myocardial infarction (AMI) during 'EuroPCR 2010' on Tuesday, May 25^th, 15:00—16:30 in room Bagatelle.